Defining intermediate-risk prostate cancer suitable for active surveillance with PSA 10-20ng/ml: Pathological outcome analysis of a population-level dataset ‌ P.E. Lonergan, C.W. Jeong, S.L. Washington, A. Herlemann, P.R. Carroll, M.R. Cooperberg

Ստացեք ամբողջական տեքստը

Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer ‌ P.E. Lonergan, S.L. Washington, S. Zhao, J.E. Cowan, H.G. Nguyen, K. Shinohara, M.R. Cooperberg, P.R. Carroll

Ստացեք ամբողջական տեքստը

Clinical utility of 4Kscore, ExosomeDx and SelectMDx and magnetic resonance imaging for the early detection of high-grade prostate cancer ‌ V. Fasulo, C.M. De la Calle, J.E. Cowan, P.E. Lonergan, M. Maggi, A.J. Gadzinsky, R.A. Yeoung, A. Saita, G. Lughezzani, R. Hurle, P. Casale, M.R. Cooperberg, K. Shinohara, P.R. Carroll, H.G. Nguyen

Ստացեք ամբողջական տեքստը